U.S., June 13 -- ClinicalTrials.gov registry received information related to the study (NCT07018492) titled 'Phase 1 Study of BPN14770 in Participants With Hepatic Impairment and Healthy Controls' on June 05.
Brief Summary: The primary purpose of this study is to assess the pharmacokinetics (PK) of BPN14770 after a single oral administration of BPN14770 in participants with mild, moderate, and severe liver impairment compared with control participants with normal hepatic function.
Study Start Date: July 07
Study Type: INTERVENTIONAL
Condition:
Hepatic Impairment
Intervention:
DRUG: BPN14770
Administered as specified in the treatment arm.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Shionogi
Published by HT Digital Content Serv...